Does the media prefer NBIX or OGN?

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Organon & Co.. MarketBeat recorded 13 mentions for Neurocrine Biosciences and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.60 beat Neurocrine Biosciences' score of -0.05 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OGN or CORT?

In the previous week, Corcept Therapeutics had 1 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Corcept Therapeutics and 4 mentions for Organon & Co.. Corcept Therapeutics' average media sentiment score of 0.85 beat Organon & Co.'s score of 0.60 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OGN or ELAN?

In the previous week, Organon & Co. had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 4 mentions for Organon & Co. and 3 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.75 beat Organon & Co.'s score of 0.60 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AXSM or OGN?

In the previous week, Axsome Therapeutics had 4 more articles in the media than Organon & Co.. MarketBeat recorded 8 mentions for Axsome Therapeutics and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.60 beat Axsome Therapeutics' score of 0.01 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Organon & Co. (OGN) Competitors

$13.72 +0.01 (+0.04%)

As of 01:05 PM Eastern

Compare

OGN vs. NBIX, CORT, ELAN, RDY, and AXSM

Should you buy Organon & Co. stock or one of its competitors? Organon & Co.'s main competitors and comparable companies include Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), and Axsome Therapeutics (AXSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Organon & Co. compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Neurocrine Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Neurocrine Biosciences has higher earnings, but lower revenue than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.08	$478.60M	$6.82	20.96
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.81

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Organon & Co.. MarketBeat recorded 13 mentions for Neurocrine Biosciences and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.60 beat Neurocrine Biosciences' score of -0.05 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences currently has a consensus price target of $202.73, indicating a potential upside of 41.85%. Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 16.88%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Neurocrine Biosciences is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.83
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neurocrine Biosciences has a net margin of 20.91% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Organon & Co.	3.41%	88.97%	6.03%

Summary

Neurocrine Biosciences beats Organon & Co. on 13 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Corcept Therapeutics?

Organon & Co. (NYSE:OGN) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Organon & Co. has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Organon & Co. has higher revenue and earnings than Corcept Therapeutics. Organon & Co. is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.81
Corcept Therapeutics	$761.41M	16.58	$99.65M	$0.42	278.07

Organon & Co. currently has a consensus price target of $11.40, indicating a potential downside of 16.88%. Corcept Therapeutics has a consensus price target of $138.17, indicating a potential upside of 18.30%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Corcept Therapeutics has a net margin of 6.52% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Corcept Therapeutics	6.52%	8.26%	6.45%

In the previous week, Corcept Therapeutics had 1 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Corcept Therapeutics and 4 mentions for Organon & Co.. Corcept Therapeutics' average media sentiment score of 0.85 beat Organon & Co.'s score of 0.60 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corcept Therapeutics beats Organon & Co. on 12 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Elanco Animal Health?

Organon & Co. (NYSE:OGN) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Organon & Co. has a net margin of 3.41% compared to Elanco Animal Health's net margin of -3.96%. Organon & Co.'s return on equity of 88.97% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Elanco Animal Health	-3.96%	8.13%	3.99%

Organon & Co. has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.81
Elanco Animal Health	$4.72B	2.34	-$232M	-$0.41	N/A

In the previous week, Organon & Co. had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 4 mentions for Organon & Co. and 3 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.75 beat Organon & Co.'s score of 0.60 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 16.88%. Elanco Animal Health has a consensus target price of $29.70, suggesting a potential upside of 34.66%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Organon & Co. beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Organon & Co. (NYSE:OGN) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

In the previous week, Organon & Co. had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Organon & Co. and 0 mentions for Dr. Reddy's Laboratories. Organon & Co.'s average media sentiment score of 0.60 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Overall Sentiment
Organon & Co.	Positive
Dr. Reddy's Laboratories	Neutral

Organon & Co. currently has a consensus price target of $11.40, suggesting a potential downside of 16.88%. Dr. Reddy's Laboratories has a consensus price target of $1,450.00, suggesting a potential upside of 11,819.44%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dr. Reddy's Laboratories has lower revenue, but higher earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.81
Dr. Reddy's Laboratories	$3.58B	2.84	$456M	$0.44	27.65

Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Organon & Co. pays out 10.4% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Organon & Co. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Organon & Co. and Dr. Reddy's Laboratories tied by winning 9 of the 18 factors compared between the two stocks.

How does Organon & Co. compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Organon & Co. (NYSE:OGN) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Organon & Co. has a net margin of 3.41% compared to Axsome Therapeutics' net margin of -24.68%. Organon & Co.'s return on equity of 88.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Organon & Co.	3.41%	88.97%	6.03%

Axsome Therapeutics presently has a consensus price target of $275.84, suggesting a potential upside of 54.73%. Organon & Co. has a consensus price target of $11.40, suggesting a potential downside of 16.88%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Axsome Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

In the previous week, Axsome Therapeutics had 4 more articles in the media than Organon & Co.. MarketBeat recorded 8 mentions for Axsome Therapeutics and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.60 beat Axsome Therapeutics' score of 0.01 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	14.62	-$183.17M	-$3.75	N/A
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.81

Summary

Organon & Co. beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGN vs. The Competition

Export

Metric	Organon & Co.	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$3.60B	$12.21B	$7.11B	$22.67B
Dividend Yield	0.58%	2.63%	2.53%	3.74%
P/E Ratio	17.81	799.68	274.41	27.77
Price / Sales	0.58	751.97	608.04	20.15
Price / Cash	2.37	81.79	77.38	39.56
Price / Book	4.75	10.39	10.90	4.64
Net Income	$187M	$2.84B	$3.50B	$1.08B
7 Day Performance	-0.15%	-1.77%	-2.15%	-1.06%
1 Month Performance	-0.44%	-6.05%	-6.41%	-5.03%
1 Year Performance	25.31%	-3.67%	8.88%	5.75%

Organon & Co. Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGN Organon & Co.	1.532 of 5 stars	$13.72 +0.0%	$11.40 -16.9%	+24.8%	$3.60B	$6.22B	17.81	10,000
NBIX Neurocrine Biosciences	4.7025 of 5 stars	$140.44 +1.5%	$201.09 +43.2%	+2.7%	$14.07B	$2.86B	20.59	2,000	Analyst Forecast
CORT Corcept Therapeutics	4.1797 of 5 stars	$115.63 -0.4%	$138.17 +19.5%	+35.3%	$12.55B	$761.41M	275.32	730
ELAN Elanco Animal Health	3.9354 of 5 stars	$22.45 +0.6%	$29.70 +32.3%	+4.7%	$11.15B	$4.72B	N/A	9,400	Analyst Forecast
RDY Dr. Reddy's Laboratories	3.4795 of 5 stars	$12.52 +2.2%	N/A	-13.7%	$10.22B	$3.58B	28.44	27,527	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:OGN) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organon & Co. (OGN) Competitors

OGN vs. NBIX, CORT, ELAN, RDY, and AXSM

How does Organon & Co. compare to Neurocrine Biosciences?

Summary

How does Organon & Co. compare to Corcept Therapeutics?

Summary

How does Organon & Co. compare to Elanco Animal Health?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organon & Co. (OGN) Competitors

OGN vs. NBIX, CORT, ELAN, RDY, and AXSM

How does Organon & Co. compare to Neurocrine Biosciences?

Which has more volatility & risk, NBIX or OGN?

Which has higher earnings & valuation, NBIX or OGN?

Does the media prefer NBIX or OGN?

Do analysts recommend NBIX or OGN?

Do institutionals & insiders have more ownership in NBIX or OGN?

Is NBIX or OGN more profitable?

Summary

How does Organon & Co. compare to Corcept Therapeutics?

Which has more volatility and risk, OGN or CORT?

Which has preferable earnings & valuation, OGN or CORT?

Do analysts prefer OGN or CORT?

Do institutionals and insiders have more ownership in OGN or CORT?

Is OGN or CORT more profitable?

Does the media favor OGN or CORT?

Summary

How does Organon & Co. compare to Elanco Animal Health?

Do institutionals and insiders hold more shares of OGN or ELAN?

Is OGN or ELAN more profitable?

Which has better valuation and earnings, OGN or ELAN?

Does the media favor OGN or ELAN?

Which has more volatility & risk, OGN or ELAN?

Do analysts recommend OGN or ELAN?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Is OGN or RDY more profitable?

Does the media refer more to OGN or RDY?

Do analysts rate OGN or RDY?

Which has stronger valuation & earnings, OGN or RDY?

Which has more volatility and risk, OGN or RDY?

Do insiders & institutionals believe in OGN or RDY?

Is OGN or RDY a better dividend stock?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Is AXSM or OGN more profitable?

Do analysts recommend AXSM or OGN?

Does the media refer more to AXSM or OGN?

Which has more volatility and risk, AXSM or OGN?

Do institutionals and insiders believe in AXSM or OGN?

Which has higher valuation & earnings, AXSM or OGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools